Dexamethasone + Lenalidomide & Multiple Myeloma (MM) / Plasmocytoma

In the context of Dexamethasone + Lenalidomide & Multiple Myeloma (MM) / Plasmocytoma, Dexamethasone + Lenalidomide is an established, on‑label regimen for multiple myeloma with both FDA and EMA approvals; “plasmocytoma” is not listed separately but is encompassed under systemic multiple myeloma.
Cruz 2016 P T. 41(5): 308-13
Merz et al. 2020 Ann Hematol 99(8): 1709-1725

Clinical data

Median OS values in both arms were the longest reported in phase III studies of Rd-based triplets in relapsed or refractory multiple myeloma at the time of this analysis…